IDH1 and glioblastoma: Most of the patients had a primary, isocitrate dehydrogenase (IDH) wildtype glioblastoma (93.9%, 92/98), while 6.1% (6/98) of the tumors had a somatic IDH mutation (classifying them as astrocytoma WHO grade 4).